David Braun, MD, PhD

Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.

Machine learning–based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.

Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.

Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.

Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.

The next gen innovator discusses the integration of fields at the International Kidney Cancer Symposium in Miami.